Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Dalbavancin Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 128,762Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fresenius Kabi Introduces Dalbavancin for Injection
    Fresenius Kabi Introduces Dalbavancin for Injection

    24 Nov 2025

    // PRESS RELEASE

    https://www.fresenius-kabi.com/us/news-and-events/fda-approved-dalbavancin-for-injection--for-single-dose-regimen-

    PRESS RELEASE
    24 Nov 2025
    Share Share
    Fresenius Kabi Launches Single-Dose Dalbavancin Injection
    Fresenius Kabi Launches Single-Dose Dalbavancin Injection

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124982440/en/Fresenius-Kabi-Introduces-Dalbavancin-for-Injection-for-single-dose-regimen-use-only

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Freseni Kabi’s Generics Dalbavancin HCl Receives Approval in US
    Freseni Kabi’s Generics Dalbavancin HCl Receives Approval in US

    10 Nov 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217591

    FDA
    10 Nov 2025
    Share Share
    Teva’s Generics Dalbavancin Hydrochloride Receives Approval in US
    Teva’s Generics Dalbavancin Hydrochloride Receives Approval in US

    23 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219465

    FDA
    23 Oct 2025
    Share Share
    Teva’s Receives First Generic Approval for Dalbavancin in US
    Teva’s Receives First Generic Approval for Dalbavancin in US

    23 Oct 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=219465

    FDA
    23 Oct 2025
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Dalbavancin Hydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Dalbavancin Hydrochloride

    08 Aug 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-dalbavancin-hydrochloride-98816.pdf

    FDA
    08 Aug 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.